Merck (NYSE:MRK) shares took a hit before hours today on first-quarter results that missed the consensus forecast. The Kenilworth, N.J.-based company posted profits of $3.2 billion, or $1.25 per share, on sales of $12.1 billion for the three months ended March 31, 2021, for a -1.2% bottom-line slide on revenues that remained almost identical year-over-year. […]
Teva Pharmaceuticals unchanged before hours on Q1 earnings beat
Teva Pharmaceuticals (NYSE:TEVA) shares stood firm before hours today on first-quarter earnings that topped the consensus forecast. The Tel Aviv, Israel-based company posted profits of $84 million, or 7¢ per share, on sales of $4 billion for the three months ended March 31, 2021, for a more-than tripled bottom-line despite a sales decline of -8.6%. […]
Canada approves J&J Vision’s drug-eluting contact lens
Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens. Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month. […]
Valeo Pharma closes upsized $6.6M private placement
Valeo Pharma announced today that it closed an upsized private placement worth more than $6.6 million. Montreal, Canada-based Valeo issued 6,645 unsecured, non-convertible debenture units at a purchase price of $1,000 per unit, totaling gross proceeds of $6.645 million, according to a news release. Each debenture unit consists of one unsecured non-convertible debenture in the […]
Timberlake appointed as Berkshire Biomedical CEO
Berkshire Biomedical announced today that it appointed John E. Timberlake as its new president and CEO. Dallas-based Berkshire Biomedical, which develops a virtual care prescription drug delivery and management system, also added Timberlake to its advisory board, according to a news release. The COPA system is designed to offer virtual care delivery using technology combined […]
FDA grants breakthrough nod for Fractyl’s type 2 diabetes treatment
Fractyl Laboratories announced today that it received FDA breakthrough device designation for its Revita DMR type 2 diabetes treatment. Lexington, Mass.-based Fractyl’s Revita DMR treatment is an outpatient endoscopic procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Preliminary clinical findings suggest that the […]
Glytec raises $21M for insulin dosing management tech
Glytec announced today that it raised $21 million in financing to fund its glycemic management technology. Waltham, Mass.-based Glytec received $9 million in debt financing from Silicon Valley Bank, combined with $12 million in equity funding, led by Savitr with contribution from other private investors, according to a news release. The company said it plans […]
Delpor doses first patient in once-yearly risperidone implant trial
Delpor announced today that it dosed the first patient in a Phase 1b/2a clinical trial for its DLP-114 risperidone implant. DLP-114 is a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. The open-label study is to evaluate the safety, tolerability and pharmacokinetics of switching from oral risperidone to the once- or twice-yearly DLP-114 […]
DarioHealth partners with MediOrbis on virtual diabetes care platform
DarioHealth (NSDQ:DRIO) announced that it launched a new virtual care initiative with MediOrbis to improve virtual care for diabetes. New York-based DarioHealth’s collaboration with MediOrbis is slated to offer eligible Medicare members with diabetes a convenient method for virtual care that includes MediOrbis’ telehealth offerings and DarioHealth’s AI-powered remote patient monitoring, according to a news […]
Glaukos inks licensing deal with Intratus for Eyelid drug delivery platform
Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform. San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed. […]
